Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lower Costs For Drug Review Personnel Are “Completely Normal” – FDA

This article was originally published in The Tan Sheet

Executive Summary

While personnel costs fall in human drug reviews, non-personnel expenses increase. The changes could indicate FDA cost containment, but also come with another user fee increase.


Related Content

Encore? FDA Could Come Close To Record 2012 NME Count This Year
PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
FDA Drug Review Costs Rise, But Personnel Spending Flattens





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts